Hyperprolactinemia Is Associated With Height Attainment Within or Above Target Height in Adult Patients With Pituitary Stalk Interruption Syndrome
Authors' conclusion
Hyperprolactinemia was associated with height attainment within or above the target height and in Chinese adult patients with PSIS. Additionally, a significant correlation was observed between hyperprolactinemia and height ≥ -2 SD.
Study context
- Population
- Adults with pituitary stalk interruption syndrome (PSIS), January 2021–September 2024; 53 males, 9 females; median age 30.5 years (range 26.0–32.4)
- Participants
- 62 adults
- Exposure
- Hyperprolactinemia vs no hyperprolactinemia
- Outcome
- Height attainment within or above target height
Main finding
As reported in the abstract
Height within or above target height
Hyperprolactinemia vs No hyperprolactinemiaOdds ratio (95% CI)P value
Unadjusted
6.4(1.6–24.7)
P = 0.007Adjusted for multiple confounders
6.89(1.19–40.81)
P = 0.032- Achieved target height
- 12 patients
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Height ≥ −2 SDHyperprolactinemiavs No hyperprolactinemiaUnadjusted | 10.5 (2.8–38.5) | P < 0.001 | |
| Height ≥ −2 SDHyperprolactinemiavs No hyperprolactinemiaAdjusted for confounders | 13.8 (2.5–77.6) | P = 0.003 | |
| 0.050.21520Odds ratio (log scale) |
Male patients
- These associations were consistently observed in male patients
Original publication
Hyperprolactinemia Is Associated With Height Attainment Within or Above Target Height in Adult Patients With Pituitary Stalk Interruption Syndrome. Endocr Pract. Published 25 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →